Research analysts at StockNews.com started coverage on shares of vTv Therapeutics (NASDAQ:VTVT - Get Free Report) in a research note issued to investors on Wednesday. The brokerage set a "sell" rating on the biotechnology company's stock.
Separately, HC Wainwright assumed coverage on shares of vTv Therapeutics in a report on Wednesday, April 9th. They issued a "buy" rating and a $36.00 price target on the stock.
Check Out Our Latest Stock Report on VTVT
vTv Therapeutics Trading Up 4.7 %
Shares of VTVT traded up $0.88 during midday trading on Wednesday, hitting $19.70. 15,172 shares of the company's stock traded hands, compared to its average volume of 23,103. vTv Therapeutics has a 1 year low of $12.12 and a 1 year high of $29.19. The firm's fifty day moving average is $18.08 and its 200-day moving average is $15.94. The stock has a market capitalization of $62.84 million, a price-to-earnings ratio of -4.35 and a beta of 0.81.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.32. The company had revenue of $0.02 million during the quarter.
Institutional Trading of vTv Therapeutics
An institutional investor recently bought a new position in vTv Therapeutics stock. JPMorgan Chase & Co. bought a new position in shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 1,803 shares of the biotechnology company's stock, valued at approximately $25,000. JPMorgan Chase & Co. owned approximately 0.06% of vTv Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 17.51% of the company's stock.
About vTv Therapeutics
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Featured Articles
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
